Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Subject disease

Experimental conditions condition of subject disease bed rest fasting... [Pg.468]

The Federal Food, Dmg and Cosmetic (FDAC) Act defines dmgs as "...articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man..." and "articles (other than food) intended to affect the stmcture of any function of the body of man." In the United States and elsewhere, the introduction of a new dmg is subject to a sequence of weU-defined stages of development and approval (4). Each stage involves either scientific testing or submission and preparation of data and analysis review (Fig. 2). [Pg.267]

The relationship between workplace exposure to airborne asbestos fibers and respiratory diseases is one of the most widely studied subjects of modern epidemiology (37—39). Asbestos-related health concerns were first raised at the beginning of the century in the UK and the latter appears to have been the first country to regulate the asbestos-user industry (40). However, at that time, infectious respiratory diseases were a much greater concern than those arising from poor industrial hygiene practices. [Pg.356]

Other Cardiovascular Agents Effecting Atherosclerosis. A large amount of clinical data is available concerning semm Upid profiles in patients subjected to dmg therapy for other cardiovascular diseases. Atheroma, for example, may be the underlying cause of hypertension and myocardial infarction. There are on the order of 1.5 million heart attacks pet year in the United States (155). [Pg.131]

Products for use on the skin are designed to improve skin quality, to maintain (or restore) skin s youthful appearance, and to aid in alleviating the symptoms of minor diseases of the skin. Many of these products are subject to different regulations in different countries. Skin products are generally formulated for a specific consumer purpose. [Pg.296]

Diseased subjects Few covariates Vulnerable persons Cause-effect Acute effects only Hazards Public acceptance... [Pg.107]

State intervention in man s activities to protect the health of the inhabitants goes back to prehistory. The motivation may not have been altogether altruistic the king acted to protect his subjects because he regarded them as his property. Public health protection began for disease control. With industrialization, came the need for control of even more hazardous forces and substances. This extended protection became technological in accident analysis and response. Present efforts in controlling risk, such as from nuclear power, are a continuation of this development. [Pg.1]

The term risk assessment is not only used to describe the likelihood of an ad crse response to a chemical or physical agent, but it has also been used to describe the likelihood of any unwanted event. This subject is treated in more detail in tlie next Part. These include risks such as explosions or injuries in tlie workplace natural catastrophes injury or deatli due to various voluntary activities such as skiing, sky diving, flying, and bimgee Jumping diseases deatli due to natural causes and many others. ... [Pg.288]

Disease refers to the number of cases existing in a population. Point-prevalence identifies the pre alcncc estimated at a given time, e.g.. the number of workers with abnormal chest films from a surv ey. Prevalence is computed as the number of cases divided by the number of study subjects at a given point in time. [Pg.326]

As yet, no human diseases have been identified as a result of FATPl mutations. However, genetic polymorphisms in the human FATPl gene have been linked to dyslipidemia. An A/G exchange at position +48 in intron 8 of the FATPl gene has been shown to result in increased TG concentrations in female but not in male subjects. In a second study, the same polymorphism was linked to increased postprandial TG concentrations and smaller low density lipoprotein (LDL) particles. To date, it is still unknown if this polymorphism is associated with altered levels of FATPl expression and/or function. [Pg.497]


See other pages where Subject disease is mentioned: [Pg.778]    [Pg.868]    [Pg.28]    [Pg.205]    [Pg.173]    [Pg.778]    [Pg.868]    [Pg.28]    [Pg.205]    [Pg.173]    [Pg.1216]    [Pg.46]    [Pg.353]    [Pg.381]    [Pg.30]    [Pg.283]    [Pg.429]    [Pg.431]    [Pg.84]    [Pg.84]    [Pg.418]    [Pg.16]    [Pg.406]    [Pg.7]    [Pg.117]    [Pg.141]    [Pg.459]    [Pg.43]    [Pg.117]    [Pg.3]    [Pg.68]    [Pg.551]    [Pg.325]    [Pg.326]    [Pg.326]    [Pg.330]    [Pg.134]    [Pg.8]    [Pg.3]    [Pg.191]    [Pg.353]    [Pg.500]    [Pg.596]    [Pg.598]    [Pg.695]    [Pg.790]   
See also in sourсe #XX -- [ Pg.136 , Pg.137 ]




SEARCH



Subject cardiovascular disease

Subject lower airway disease

© 2024 chempedia.info